Antibody-drug conjugates (ADCs) represent the most successful class of active targeting drug-delivery systems, however, despite the increasing number of FDA approvals treatment-related adverse events ...
ADC is a monoclonal antibody covalently bound to cytotoxic chemical substances (payload) through linker. ADC linker plays a key role in the therapeutic effect of ADC, and its characteristics greatly ...
Antibody-drug conjugates (ADCs) have been in development for decades, but only about a dozen have received FDA approval. Clearly, ADCs still have some major challenges. Yet they have done little to ...
In this free webinar, explore recent developments in next-generation antibody-drug conjugates (ADCs) and emerging strategies in ADC conjugation and linker design. Attendees will learn how ...
The addition of the linker should not induce aggregation and needs to ensure acceptable PK characteristics, while limiting the premature release of the payload in plasma and enabling the effective ...
- Lantern will evaluate and potentially develop ADC programs with novel patent protected linkers, drug payloads and conjugation processes from Califia that have demonstrated enhanced, highly targeted ...
Over the last several decades, mounting interest has positioned bioconjugate therapeutics as one of the most promising biopharmaceutical modalities. Work in chemical biology, including novel ...
Biopharmaceutics is a rapidly growing research field that aims at producing viable therapeutic and prophylactic treatments for many diseases. The use of biological therapies has increased ...
Ideally, anti-cancer treatments should specifically target and kill tumour cells while leaving normal, healthy tissues relatively unscathed. The therapeutic ratio of the maximum tolerated to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results